DATA COLLABORATIONS

Accelerate therapy development with real-world multimodal data

Advance discovery, innovation, and increase the likelihood of trial success with real-world clinical and molecular data, including DNA, RNA and whole slide pathology images.

Supporting Key Development Milestones

UPCOMING WEBINAR:
Discover novel biomarkers

Leverage real-world multimodal data and bioinformatics expertise to identify disease subtypes and power discovery approaches to lead to novel therapeutic opportunities
Read case study
UPCOMING WEBINAR:
Generate and validate hypotheses

Analyze your target of interest and identify the most appropriate patient population to evaluate for your therapy program
Read case study
UPCOMING WEBINAR:
Design late stage clinical trials

Design trials, validate biomarker strategies, define optimal populations to study and assess execution feasibility.
Read case study

THURSDAY, NOVEMBER 21 @ 10 AM PT / 12 PM CT / 1 PM ET

Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence

During this engaging session, you will: delve into the evolving landscape of outcomes research with a focus on real-world evidence (RWE) and advanced analytics; explore how integrating multimodal data — including clinical, molecular, imaging, and claims data — can transform pharmaceutical research and healthcare decision-making; and learn from industry experts on how to leverage outcomes data for regulatory submissions, market access, and clinical decision making to drive innovation and improve patient outcomes across the continuum of care.

Register now

Tempus lens

The full power of Tempus data at your fingertips

Lens enables you to analyze Tempus’ library of 6M+ de-identified research records, helping to uncover critical insights that can accelerate innovation and improve patient outcomes.

Explore now

How We Partner

Tempus establishes joint research teams combining disciplines from computational biology, medical, bioinformatics, and machine learning to work alongside your teams with a goal of accelerating therapy development.

Tempus Explore

Tempus bioinformatics experts help you answer your oncology research questions and meet your research objectives efficiently

Data Licenses

Our data licensing partnership provides you with access to de-identified multimodal data to support iterative research and development objectives using the tools you are most comfortable with

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

WE’VE PARTNERED WITH

95%

of the top 20 pharma oncology companies
200+

biopharma companies

We are very pleased to collaborate with Tempus to enhance our data-driven R&D strategy and glean critical insights that will deepen our understanding of complex tumor biology, enhance access to predictive preclinical models, and increase the probability of clinical success across our diverse pipeline.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Learn more about our partnership with AstraZeneca

We are looking forward to working together now and in the future, as we continue to progress our current clinical candidates, test rational combinations, and bring forward new ones, with the goal of getting medicines to patients as quickly as possible.

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Learn more about our partnership with Kronos Bio

Our collaboration with Tempus provided valuable insights to prioritize disease indications based on target expression and its relationship with clinical outcomes. The breadth of the Tempus database allowed us to correlate response of many standard therapeutic regimens to target expression to support our clinical trial plans.

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Tempus is a leader in the field of personalized medicine, and like Genmab, Tempus has a mission to improve the lives of cancer patients. We are looking forward to expanding our exciting partnership with them and to the possibility of discovering important new oncology targets and biomarkers.

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

~7M

de-identified research records to power scientific discovery
1M+

records with imaging data
1M+

records with matched clinical data linked with genomic information
250K+

records with whole transcriptomic profiles
50x larger

database than The Cancer Genome Atlas, the largest public genomic database

News & Insights

view all RESOURCES

UPCOMING WEBINAR:
Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape
Watch replay
UPCOMING WEBINAR:
Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment
Watch now
UPCOMING WEBINAR:
The strategic collaboration will leverage Tempus’ large multimodal datasets to enhance BioNTech’s next-generation oncology pipeline Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”)
Read press release
UPCOMING WEBINAR:
Hear from Tempus scientists on how biopharma organizations uncover critical insights within Tempus’ multimodal database using Lens to facilitate faster-time-to-insight and accelerate research and development
Watch replay
UPCOMING WEBINAR:
How AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch
Read case study
UPCOMING WEBINAR:
Mirati Therapeutics leverages Tempus data to revise its KRAS strategy and refine its patient selection approach
Read case study

DATA COLLABORATIONS

Accelerate therapy development with real-world multimodal data

Supporting Key Development Milestones

Discover novel biomarkers

Generate and validate hypotheses

Design late stage clinical trials

Precision outcomes research: Shaping the future of oncology biopharma with real-world evidence

Tempus lens

The full power of Tempus data at your fingertips

How We Partner

Tempus Explore

Data Licenses

Top pharmaceutical and biotech companies trust Tempus to inform therapy development

WE’VE PARTNERED WITH

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca

Jorge DiMartino, M.D., Ph.D., Chief Medical Officer and Executive Vice President, Clinical Development, Kronos Bio

Jonghwa Won, Executive Vice President, Head of Early Development, ABL Bio

Jan van de Winkel, Ph.D., Chief Executive Officer, Genmab

The Tempus Difference

News & Insights

Industry experts discuss the integration of diverse omics data, from next-generation sequencing (NGS) to proteomics, and explore its transformative impact on the research landscape

Industry leaders highlight the importance of multimodal data, AI-driven diagnostics, and the necessity of innovative approaches to meet the challenges of oncology treatment

Hear from Tempus scientists on how biopharma organizations uncover critical insights within Tempus’ multimodal database using Lens to facilitate faster-time-to-insight and accelerate research and development

How AstraZeneca simplified its approach to TROPION-Lung01 and drove down time to launch

Mirati Therapeutics leverages Tempus data to revise its KRAS strategy and refine its patient selection approach

Other Solutions for Life Sciences

See how one of the industry’s largest, structured real-world datasets can support you throughout the therapy development process.